Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, Rolf Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014
Cited by 950 works. doi:10.1016/s1470-2045(13)70586-2
Authors
- Martin Reck
- Rolf Kaiser
- Anders Mellemgaard
- Jean‐Yves Douillard
- С. В. Орлов
- Maciej Jerzy Krzakowski
- Joachim von Pawel
- Maya Gottfried
- Igor Bondarenko
- Meilin Liao
- Claudia-Nanette Gann
- José Barrueco
- Birgit Gaschler‐Markefski
- Silvia Novello
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Discrete Sequential Boundaries for Clinical Trials
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Comprehensive genomic characterization of squamous cell lung cancers
- A note on quantifying follow-up in studies of failure time
- GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10